

Intellia Therapeutics, Inc.  
Form 8-K  
November 04, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): November 1, 2016**

**INTELLIA THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-37766**  
**(Commission**

**File Number)**

**36-4785571**  
**(I.R.S. Employer**

**Identification No.)**

**130 Brookline Street, Suite 201,**

**Cambridge, Massachusetts**  
**(Address of principal executive offices)**

**02139**  
**(Zip Code)**

**Registrant's telephone number, including area code: (857) 285-6200**

**Not Applicable**

**Former name or former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 1, 2016, Rachel Haurwitz, Ph.D. informed the Board of Directors (the Board) of Intellia Therapeutics, Inc. (the Company) of her resignation from the Board, effective as of the same date. Dr. Haurwitz's decision to resign from the Board is based on her desire to focus on the research and development efforts at Caribou Biosciences, Inc., where she serves as president and chief executive officer. Her decision did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Intellia Therapeutics, Inc.**

Date: November 4, 2016

By: /s/ Nessian Bermingham  
Nessian Bermingham, Ph.D.

President and Chief Executive Officer